GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST

Their core work

Great Ormond Street Hospital (GOSH) is one of the world's leading paediatric hospitals, based in London, specializing in the treatment of rare and complex childhood diseases. In EU research, GOSH contributes deep clinical expertise in gene therapy, rare genetic disorders, and prenatal treatment — bringing real patient populations and clinical trial infrastructure to translational research consortia. Their H2020 work focuses on moving advanced therapies (gene correction, stem cell transplantation) from lab bench to bedside for conditions like severe combined immunodeficiency (SCID), osteogenesis imperfecta, and Duchenne muscular dystrophy.

What they specialise in

How they've shifted over time

GOSH's early H2020 work (2016–2019) centred on bone disorders and immunodeficiency — prenatal stem cell therapy for brittle bone disease (BOOSTB4) and gene medicines for SCID (SCIDNET). Their later projects (2018–2024) shifted toward broader gene therapy applications and neurological phenotyping, with RECOMB continuing the SCID gene therapy line while BIND opened a new direction exploring brain involvement in Duchenne muscular dystrophy. The trajectory shows a hospital deepening its gene therapy credentials while branching into neurodevelopmental research linked to genetic conditions.

GOSH is expanding from single-gene correction therapies into understanding the broader neurological impacts of genetic diseases, suggesting future interest in combined gene therapy and neurodevelopmental outcome studies.

How they like to work

GOSH participates exclusively as a partner, never leading H2020 consortia — consistent with a clinical institution that provides patient cohorts, clinical trial sites, and specialist medical expertise rather than managing large research programmes. With 48 unique partners across 14 countries from just 4 projects, they work in sizeable international consortia typical of rare disease research. This makes them a reliable, well-connected clinical partner who brings credibility and patient access without competing for coordination roles.

GOSH has collaborated with 48 distinct partners across 14 countries through just 4 projects, indicating participation in large, well-funded rare disease consortia with broad European reach. Their network spans clinical centres, universities, and biotech companies focused on advanced therapies.

What sets them apart

GOSH is not a university lab — it is a world-renowned children's hospital with direct access to paediatric patient populations affected by rare genetic diseases. This gives consortium partners something extremely difficult to find elsewhere: a clinical site with both the ethical approvals and the specialist medical teams needed to run advanced therapy trials in children. For any consortium developing gene therapies, cell therapies, or diagnostic tools for rare paediatric conditions, GOSH provides the critical translational bridge from preclinical research to real clinical outcomes.

Highlights from their portfolio

• BOOSTB4
  Largest GOSH project by funding (EUR 1.08M) — pioneering prenatal stem cell transplantation for osteogenesis imperfecta, an exceptionally ambitious approach treating patients before birth.
• BIND
  Opens a new research direction for GOSH — exploring brain involvement and cognitive impacts (autism, learning difficulties) in Duchenne muscular dystrophy through deep phenotyping and animal models.
• SCIDNET
  Part of a sustained GOSH commitment to SCID gene therapy alongside RECOMB, demonstrating long-term institutional investment in curing this life-threatening immunodeficiency in children.